

PUBLICATIONS

- 1. Theoretical calculations for neighboring group participation in gas-phase elimination kinetics of 2-hydroxyphenylethyl chloride and of 2-methoxyphenethyl chloride**
Brusco, Y; [Berroterán, N](#); Loroño, M; Córdova, T; Chuchani, G.
J Phys Org Chem (2009), 22:1022-1029.
- 2. DFT and ab initio study on the reaction mechanisms of the homogenous, unimolecular elimination kinetics of selected 1-chloroalkenes in the gas phase**
Mora, J; Lezama, J; [Berroterán, N](#); Córdova, T; Chuchani, G.
Int J Quantum Chem (2012), 112:3729-3738.
- 3. Radiosynthesis and first preclinical evaluation of the novel norepinephrine transporter PET-ligand [¹¹C]Me@HAPTHI**
Rami-Mark, C; [Berroterán-Infante, N](#); Philippe, C; Foltin, S; Vraka, C; Hoeping, A; Lanzenberger, R; Hacker, M; Mitterhauser, M; Wadsak, W.
EJNMMI Res (2015), 5:34.
- 4. [¹⁸F]FMeNER-D2: A systematic in vitro analysis of radio-metabolism**
Rami-Mark, C; Eberheer, N; [Berroterán-Infante, N](#); Vanicek, T; Nics, L; Lanzenberger, R; Hacker, M; Wadsak, W; Mitterhauser, M.
Nuc Med Biol (2016), 43:490-495.
- 5. Simple and rapid quantification of serotonin transporter binding using [¹¹C]DASB bolus plus constant infusion**
Gryglewski, G; Rischka, L; Philippe, C; Hahn, A; James, GM; Klebermass, EM; Hienert, M; Silberbauer, L; Vanicek, T; Kautzky, A; [Berroterán-Infante, N](#); Nics, L; Traub-Weidinger, T; Mitterhauser, M; Wadsak, W; Hacker, M; Kasper, S; Lanzenberger, R.
Neuroimage (2017), 149:23-32.
- 6. Development of a radiolabeled caninized anti-EGFR antibody for comparative oncology trials**
Fazekas-Singer, J; [Berroterán-Infante, N](#); Rami-Mark, C; Dumanic, M; Matz, M; Willmann, M; Andreae, F; Singer, J; Wadsak, W; Mitterhauser, M; Jensen-Jarolim, E.
Oncotarget (2017), 8:83128-83141.
- 7. Assessment of ketamine binding of the serotonin transporter in humans with positron emission tomography**
Spies, M; James, GM; [Berroterán-Infante, N](#); Ibeschitz, H; Kranz, GS; Unterholzner, J; Godbersen, MG; Gryglewski, G; Hienert, M; Jungwirth, J; Pichler, V; Reiter, B; Winkler, D; Mitterhauser, M; Stimpfl, T; Hacker, M; Kasper, S; Lanzenberger, R.
Int J of Neuropsychopharm (2018), 21:145-153.
- 8. Preclinical in vitro and in vivo evaluation of [¹⁸F]FE@SUPPY for cancer imaging: Limitations of a xenograft model for colorectal cancer**
Balber, T; Singer, J; [Berroterán-Infante, N](#); Dumanic, M; Fetty, L; Fazekas-Singer, J; Vraka, C; Nics, L; Bergmann, M; Pallitsch, K; Spreitzer, H; Wadsak, W; Hacker, M; Jensen-Jarolim, E; Viernstein, H; Mitterhauser, M.
Contrast Media Mol Imaging, 2018, 2018: Article ID 1269830.
- 9. [¹⁸F]FEPPA: Improved automated radiosynthesis, binding affinity and preliminary in vitro evaluation in colorectal cancer**
[Berroterán-Infante, N](#); Balber, T; Furlinger, P; Bergmann, M; Lanzenberger, R; Hacker, M; Mitterhauser, M; Wadsak, W.
ACS Med Chem Lett (2018), 9:177-181.

- 10. An overview on PET radiochemistry: part 1 – covalent labels – ^{18}F , ^{11}C and ^{13}N**
Pichler, V; [Berroterán-Infante, N](#); Philippe, C; Vraka, C; Klebermass, EM; Balber, T; Pfaff, S; Nics, L; Mitterhauser, M; Wadsak W.
J Nuc Med (2018), 59:1350-1354.
- 11. L-[S-methyl- ^{11}C]methionine – an example of radiosynthetic optimization**
Pichler, V; Vraka, C; [Berroterán-Infante, N](#); Krcal, A; Eidherr, H; Traub-Weidinger, T; Hacker, M; Mitterhauser, M; Wadsak, W.
Appl Radiat Isot (2018), 141:107-111.
- 12. Molar activity - The keystone in ^{11}C -radiochemistry: An explorative study using the gas phase method**
Pichler, V; Zenz, T; Philippe, C; Vraka, C; [Berroterán-Infante, N](#); Pfaff, S; Nics, L; Ozenil, M; Langer, O; Willeit, M; Traub-Weidinger, T; Lanzenberger, R; Mitterhauser, M; Hacker, M; Wadsak, W.
Nucl Med Biol (2018), 67:21-26.
- 13. [^{68}Ga]Ga-PSMA-11 ligand PET/MRI for newly diagnosed prostate cancer: staging performance and clinical impact**
Grubmüller, B; Baltzer, P; Hartenbach, S; D'Andrea, D; Helbich, T; Haug, AR; Goldner, GM; Wadsak, W; Pfaff, S; Mitterhauser, M; Balber, T; [Berroterán-Infante, N](#); Grahovac, M; Babich, J; Seitz, C; Kramer, G; Sasani, M; Mazal, P; Kenner, L; Rausch, I; Shariat, SF; Hacker, M; Hartenbach, M.
Clin Cancer Res (2018), 24:6300-6307
- 14. Parcellation of the human cerebral cortex based on molecular targets using PET**
James, GM*; Gryglewski, G*; Vanicek, T; [Berroterán-Infante, N](#); Philippe, C; Kautzy A; Nics, L; Godbersen, G; Vraka, C; Unterholzner, J; Sigurdardottir LH; Spies, M; Kranz G; Hahn, A; Mitterhauser, M; Wadsak, W; Bauer, A; Hacker, M; Kasper, S; Lanzenberger, R
Cereb Cortex (2019), 29:372-382.
- 15. Optimization of the automated synthesis of [^{11}C]mHED – administered and apparent molar activities**
Vraka, C; Pichler, V; [Berroterán-Infante, N](#); Wollenweber, T; Pillinger, A; Hohensinner, M; Fetty, L; Beitzke, D; Li, X; Philippe, C; Pallitsch, K; Mitterhauser, M; Hacker, M; Wadsak, W.
Pharmaceuticals (2019), 12:12.
- 16. Binding Affinity of some Endogenous and Synthetic TSPO Ligands Regarding the rs6971 polymorphism**
[Berroterán-Infante, N](#); Tadic, M; Hacker, M; Wadsak, W; Mitterhauser, M.
Int J Mol Sciences (2019), 20:563.
- 17. Dynamic [^{18}F]FET-PET-MRI using MRI-based attenuation correction methods**
Rausch, I; Zitterl, A; [Berroterán-Infante, N](#); Rischka, L; Prayer, D; Fenchel, M; Saresghi, R; Haug, AR; Beyer, T; Traub-Weidinger, T.
Eur Radiology (2019), In Press.
- 18. Synthesis and in vitro evaluation of new translocator protein ligands designed for positron emission tomography**
[Berroterán-Infante, N](#)*; Kalina, T*; Schmitl, S; Vraka, C; Hacker, M; Mitterhauser, M; Wadsak, W, Pallitsch, K.
*Equally contributed.
Future Med Chem (2019), In Press.

19. Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging

Gryglewski, G; Klöbl, M; Berroterán-Infante, N; Rischka, L; Balber, T; Vanicek, T; Pichler, V; Kautzky, A; Klebermass, EM; Reed, MB; Hienert, M; James, GM; Silberbauer, L; Godbersen, GM; Unterholzner, J; Michenthaler, P; Hartenbach, M; Winkler-Pjrek, E; Wadsak, W; Mitterhauser, M; Hahn, A; Hacker, M; Kasper, S; Lanzenberger, R.
Eur Neuropsychopharmacology, In Review.

20. (R)-[¹⁸F]NEBIFQUINIDE: A Tale of a Third Generation TSPO PET Tracer

Berroterán-Infante, N; Kalina, T; Fetty, L; Janisch, V; Velasco, R; Vraka, C; Hacker, M; Haug, AR; Pallitsch, K; Wadsak, W; Mitterhauser, M.
J Med Chem, In Review.

21. Association of norepinephrine transporter methylation on in vivo NET expression and hyperactivity-impulsivity symptoms in ADHD measured with PET

Sigurdardottir, HL; Kranz, GS; Rami-Mark, C; James, GM; Vanicek, T; Gryglewski, G; Berroterán-Infante, N; Kautzky, A; Hienert, M; Traub-Weidinger, T; Mitterhauser, M; Wadsak, W; Hartmann, A; Hacker, M; Rujescu, D; Kasper, S; Lanzenberger, R.
Mol Psychiatry, In Review.

22. Toward the optimization of (+)-[¹¹C]PHNO: synthesis time reduction and process validation

Pfaff, S; Philippe, C; Nics, L; Berroterán-Infante, N; Pallitsch, K; Rami-Mark, C; Willeit, M; Weidenauer, A; Sauerzopf, U; Mitterhauser, M; Hacker, M; Wadsak, W; Pichler, V.
Contrast Media Mol Imaging, In Review.

23. On the relationship of first-episode psychosis to the amphetamine-sensitized state

Weidenauer, A; Bauer, M; Sauerzopf, U; Bartova, L; Nics, L; Philippe, C; Pichler, V; Berroterán-Infante, N; Meyer, B; Rabl, U; Cumming, P; Pfaff, S; Stimpfl, T; Sitte, HR; Lanzenberger, R; Zimprich, A; Rusjan, P; Dorffner, G; Mitterhauser, M; Pezawas, L; Kasper, S; Wadsak, W; Praschak-Rieder, N; Willeit, M.
Nature Neuroscience, Submitted.